Summary CUMYL-PINACA also referred to as SGT-24, belongs to the class of indazole-3-carboxamide synthetic cannabinoids. It is a robust agonist for cannabinoid receptors, demonstrating about threefold selectivity for CB1. Its affinity for human CB1 receptors is notably high, with an EC50 of 0.15nM, and it exhibits a similar potency for human CB2 receptors, with an …
Summary CUMYL-4CN-BINACA, also known as CUMYL-CYBINACA or SGT-78, is an indazole-3-carboxamide-based synthetic cannabinoid that has been distributed online as a designer drug. This compound acts as a potent agonist for CB1 and CB2 cannabinoid receptors, with EC50 values of 0.58 nM and 6.12 nM, respectively, as demonstrated in in vitro studies.In animal models, CUMYL-4CN-BINACA has …
Summary APP-FUBINACA is a synthetic cannabinoid based on the indazole structure, and it has been distributed online as a designer drug. Regarding its pharmacological profile, research has indicated that APP-FUBINACA exhibits only moderate binding affinity for the CB1 receptor, with a Ki value of 708 nM. However, specific data regarding its EC50 has yet to …
Summary APINACA, also known as AKB48 or N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, is a substance that functions as a reasonably potent agonist for cannabinoid receptors. It exhibits full agonist activity at the CB1 receptor, with an EC50 of 142 nM and a Ki of 3.24 nM. To provide context, this Ki value is notably lower than that of Δ9-THC …
Summary AMB-CHMINACA, alternatively known as MMB-CHMINACA or MA-CHMINACA, belongs to the family of indazole-based synthetic cannabinoids. Notably, it exhibits strong agonistic activity towards the CB1 receptor and has entered the online market as a designer drug. Identifiers IUPAC name CAS Number 1863066-03-8(racemate) PubChem CID 119026010 ChemSpider 32055578 UNII OU56JJP891Y21A13WADY(racemate) Chemical and physical data Formula C21H29N3O3 …
Summary ADSB-FUB-187, an indazole-based synthetic cannabinoid, exhibits remarkable potency as a CB1 receptor agonist, boasting an impressively low binding affinity with a Ki value of 0.09 nM and an EC50 of 1.09 nM. Pfizer’s 2009 patent, WO 2009/106982, introduced this compound as example 187. While it stands out as the most tightly binding substance within …
Summary ADB-PINACA, a cannabinoid designer drug, finds its place as a constituent in certain synthetic cannabis products. It stands out as a robust agonist of both the CB1 and CB2 receptors, boasting impressive EC50 values of 0.52 nM and 0.88 nM, respectively. Notably, akin to MDMB-FUBINACA, this compound incorporates a tert-leucine amino acid residue Identifiers …
Summary ADB-FUBINACA, a synthetic designer drug, initially surfaced in synthetic cannabis mixtures in Japan back in 2013. Notably, by 2018, it had risen to become the third most frequently detected synthetic cannabinoid in drug seizures by the Drug Enforcement Administration.The (S)-enantiomer of ADB-FUBINACA was detailed in a Pfizer patent dating back to 2009. This enantiomer …
Summary ADB-CHMINACA, also recognized as MAB-CHMINACA, belongs to the class of indazole-based synthetic cannabinoids. Initially designed by Pfizer in 2009 for its potential as an analgesic medication, it stands out as a robust agonist of the CB1 receptor, boasting an impressive binding affinity with a Ki value as low as 0.289 nM. This compound gained …
Summary ADB-BINACA is a synthetic cannabinoid designer drug that has been identified as a component in certain synthetic cannabis formulations. Initially conceived by Pfizer for its potential analgesic properties, this compound is a robust agonist for the CB1 receptor, boasting an impressive binding affinity (Ki) of 0.33 nM and an EC50 of 14.7 nM. Identifiers …
